Dose-dependent red blood cell volume increase induced by bepridil

Area of Science:

• Pharmacology
• Hematology
• Biochemistry

Background:

• Sickle cell disease (SCD) is a genetic blood disorder characterized by the sickling of red blood cells (RBCs).
• Sickling is caused by the polymerization of deoxygenated sickle hemoglobin (Hb S).
• Current treatments for SCD are limited, necessitating research into novel therapeutic agents.

Purpose of the Study:

• To investigate the in vitro effects of Bepridil on red blood cells from SCD patients.
• To determine the mechanism by which Bepridil inhibits RBC sickling.

Main Methods:

• Bepridil's effect on RBC sickling was assessed at micromolar concentrations.
• RBC osmotic swelling and mean corpuscular hemoglobin concentration (MCHC) were measured.
• Hemoglobin binding affinity and RBC partition coefficient were determined using equilibrium dialysis and partition coefficient measurements, respectively.

Main Results:

• Bepridil inhibited RBC sickling in a dose-dependent manner.
• Bepridil induced RBC osmotic swelling and decreased MCHC.
• Decreased MCHC correlated with delayed Hb S polymerization and reduced sickling.
• Bepridil exhibited low binding affinity to hemoglobin (Kb = 10(3)/M) and an RBC partition coefficient (Kp = 1-3 x 10(3)) similar to other amphipathic molecules.

Conclusions:

• Bepridil demonstrates potential as an antisickling agent by reducing MCHC and delaying Hb S polymerization.
• The mechanism involves osmotic swelling of RBCs, leading to inhibition of sickling.
• Further research into Bepridil's therapeutic application for SCD is warranted.